Chemours price target lowered to $30 from $35 at BMO Capital

BMO Capital lowered the firm’s price target on Chemours to $30 from $35 and keeps an Outperform rating on the shares. The Q2 results and Q3 guidance were choppy, but the 2025 picture is clearing up, with all three businesses likely to inflect upward, the analyst tells investors in a research note.